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Abstract
Dabigatran is effective in decreasing the risk of ischaemic stroke in patients with atrial fibrillation. However, like all
anticoagulants, it is associated with a risk of bleeding. In cases of trauma or emergency surgery, emergency reversal
of dabigatran-induced anticoagulation may be required. A specific reversal agent for dabigatran, idarucizumab, has
been approved by the US Food and Drug Administration. Alternative reversal agents are available, such as
prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs). In this review we evaluate the role of PCCs
and aPCCs in the reversal of dabigatran anticoagulation and consider which tests are appropriate for monitoring
coagulation in this setting. Pre-clinical studies, small clinical studies and case reports indicate that PCCs and aPCCs
may be able to reverse dabigatran-induced anticoagulation in a dose-dependent manner. However, dosing based
on coagulation parameters can be difficult because available assays may not provide adequate sensitivity and
specificity for measuring anticoagulation induced by dabigatran or the countering effects of PCCs/aPCCs. In
addition, PCCs or aPCCs can potentially provoke thromboembolic complications. Despite these limitations and the
fact that PCCs and aPCCs are not yet licensed for dabigatran reversal, their use appears to be warranted in patients
with life-threatening haemorrhage if idarucizumab is not available.
Keywords: Anticoagulation, Activated prothrombin complex concentrate, Bleeding, Dabigatran, Prothrombin
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Background
For more than 60 years, the only oral anticoagulants
available for the prevention of ischaemic stroke in pa-
tients with non-valvular atrial fibrillation (AF) have been
the vitamin K antagonists (VKAs), such as warfarin,
phenprocoumon and acenocoumarol [1]. However, the
need for coagulation monitoring and dose adjustments,
as well as concerns about drug–drug or diet–drug inter-
actions and the risk of bleeding, have restricted the use
of VKAs for ischaemic stroke prevention in patients with
AF [2, 3]. Several direct oral anticoagulants (DOACs)
have been approved for this indication: the oral direct
thrombin inhibitor dabigatran, and oral direct factor Xa
inhibitors (e.g. rivaroxaban, apixaban or edoxaban) [4, 5].
Compared with VKAs, DOACs produce a more predict-
able anticoagulant effect and can be given in fixed doses
without routine coagulation monitoring. The results of
randomised controlled trials (RCTs) and observational
studies indicate that DOACs are at least as effective as
VKAs for stroke prevention in patients with AF, with re-
duced rates of intracranial bleeding and, at certain doses,
a reduction in life-threatening bleeding [6–10].
Dabigatran, the active moiety of dabigatran etexilate,
has a rapid onset of action, and the plasma concentra-
tion peaks within 0.5–2.0 hours of administration [11].
This anticoagulant has a half-life of 7–17 hours [12] and
is eliminated predominantly via renal excretion (80 %)
[13]. Dabigatran is licensed in many countries for several
indications, including: primary prevention of venous
thromboembolism (VTE) in patients who have undergone
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elective total hip or knee arthroplasty (150 mg or 220 mg
once daily); prevention of ischaemic stroke and systemic
embolism in adult patients with non-valvular AF (110 or
150 mg twice daily, except in the USA where 75 and
150 mg twice-daily doses are approved); and treatment of
acute deep vein thrombosis (DVT) and pulmonary embol-
ism (110 and 150 mg twice daily, except in the USA where
only the 150 mg twice-daily dose is approved) [14, 15].
Most episodes of bleeding in patients treated with dabi-
gatran can be managed with supportive measures and by
temporarily withholding the drug. However, additional
strategies may be needed in patients with life-threatening
bleeding and those who require urgent or emergency sur-
gery or other invasive procedures for which haemostasis is
necessary. Supportive care is also not sufficient in pa-
tients with intracranial bleeding, where outcome may
be directly associated with the time needed for coagu-
lation reversal [16].
A specific reversal agent for dabigatran, idarucizumab,
has been approved by the US Food and Drug Administra-
tion. Animal models and phase I–III clinical data show
that idarucizumab achieves predictable, complete and sus-
tained reversal of dabigatran, with the potential for signifi-
cant reductions in blood loss [17–19]. In an interim
analysis of the phase III RE-VERSE AD study [19], involv-
ing 90 dabigatran-treated patients with serious bleeding or
in need of an urgent surgical procedure, idarucizumab
completely reversed the effects of dabigatran within mi-
nutes. Idarucizumab appears to be well tolerated, and it
has no direct effects on procoagulant or anticoagulant ac-
tivity [17, 19]. However, idarucizumab is yet to be ap-
proved in many countries and, pending its widespread
availability, multiple therapeutic options have been sug-
gested for emergency reversal of dabigatran’s anticoagu-
lant effects. These options include prothrombin complex
concentrates (PCCs) and activated PCCs (aPCCs), as well
as recombinant activated factor VII (rFVIIa) [20–24].
In this article we review pre-clinical and clinical evidence
for the use of PCCs and aPCCs to restore haemostasis in
dabigatran-treated patients with either haemorrhage or the
need for an urgent surgical procedure, and review the
role of laboratory coagulation assessments in this set-
ting [20–24].
Mechanism of action of dabigatran
Dabigatran is a small molecule that binds competitively
and selectively to the catalytic site of thrombin [25, 26].
Since thrombin facilitates coagulation by converting fi-
brinogen into a fibrin network, dabigatran has the effect
of blocking the terminal coagulation cascade (Fig. 1)
[27]. Additional effects of thrombin prevented by dabi-
gatran include platelet activation, amplification of coagu-
lation activation (positive feedback mechanism) and
inhibition of fibrinolysis [25].
Pre-surgical management of the dabigatran-
anticoagulated patient
Because dabigatran has a short half-life (in patients with
normal renal function) and its effects on thrombin are
reversible, the general recommendation for dabigatran-
treated patients scheduled to receive elective surgery is
to discontinue therapy temporarily and wait for the
remaining drug to be eliminated naturally. The timing of
discontinuation before elective surgery is based on a pa-
tient’s renal function and risk of bleeding, and the type
of surgery planned. In patients with normal renal func-
tion, dabigatran should be stopped at least 24 hours be-
fore surgery with a standard risk of bleeding; a 48-hour
interim is appropriate if the risk of bleeding is high [15].
These time periods increase to 2–3 days and 4 days, re-
spectively, in patients with reduced renal function (cre-
atinine clearance ≥30–50 ml/min) [28].
General bleeding management of the dabigatran-
anticoagulated patient
Expert and professional society guidelines are available re-
garding emergency bleeding management in patients re-
ceiving dabigatran treatment [28–32]. There are variations
in the specifics but the principles are consistent across dif-
ferent guidelines. The general approach to managing non-
emergency bleeding complications is similar to that with
pre-surgical management, i.e. discontinue dabigatran ther-
apy temporarily and wait for the elimination of dabigatran.
In this review, we will focus on major or life-threatening
Fig. 1 The coagulation cascade [27]. The common pathway shows
the dependence of coagulation on the action of thrombin. Permission
for reproducing this figure has been requested from John Wiley and
Sons, Inc. aPTT activated partial thromboplastin time, PL phospholipase,
PT prothrombin time
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bleeding (including intracranial bleeding) and emergency
surgery, where a need for more rapid reversal of the ef-
fects of dabigatran necessitates a different strategy. Ex-
ogenous coagulation factor repletion with PCCs or aPCCs
has been suggested as a potential treatment option in
these settings [33].
The initial steps of bleeding management algorithms
typically consist of local/surgical haemostasis where ap-
propriate, qualitatively assessing anticoagulant activity
(e.g. by activated partial thromboplastin time (aPTT)),
and general measures such as volume replacement and
blood product transfusion. Medical history including
anticoagulant intake is integral to the early phase of
treatment. In many cases, however, anticoagulation may
not be contributing meaningfully to the bleeding and so
reversal of dabigatran is not usually a first-line priority.
In the RE-VERSE AD study [19], 22 out of 90 enrolled
patients did not have prolonged diluted thrombin times
(dTTs) due to the natural clearance of dabigatran. Ac-
quired coagulopathy can develop secondary to blood loss,
loss and consumption of coagulation factors and haemodi-
lution owing to excessive fluid replacement. This is a
major risk factor for progression from initial bleeding to
severe haemorrhage. There is some evidence suggesting
that ‘restrictive’ or goal-directed as opposed to ‘liberal’
fluid resuscitation strategies may reduce morbidity and
lengths of hospital stay [34, 35]. However, other investiga-
tions have cast doubt on the benefits of a restrictive ap-
proach [36] and, importantly, hypovolaemia can cause
acidosis, thereby exacerbating coagulopathy. In the pres-
ence of substantial tissue injury and haemorrhagic shock,
activation of protein C and subsequent hyperfibrinolysis
may also aggravate coagulopathy [37]. Early intervention
with haemostatic therapy (e.g. fibrinogen concentrate,
cryoprecipitate, fresh frozen plasma, platelets) may be crit-
ical for preventing complex coagulopathies and progres-
sion to severe, life-threatening haemorrhage—especially in
patients who have bled so that they have acquired coagu-
lopathy in addition to anticoagulant therapy. Multimodal
therapy should therefore be administered as early as pos-
sible in life-threatening bleeding under dabigatran antic-
oagulation [38].
Laboratory evaluation of dabigatran concentration
Although patients taking dabigatran do not need to
undergo routine coagulation monitoring, rapid assess-
ment of whether or not the patient is actively antico-
agulated is important in an emergency situation. This
information can help determine the contribution of antic-
oagulation to the bleeding, the need for a reversal/reple-
tion strategy and whether an invasive procedure should be
delayed [39, 40].
A variety of tests have been explored for the detection or
quantification of plasma dabigatran activity, but limitations
are common. For example, the prothrombin time (PT)
and the international normalised ratio (INR) exhibit low
sensitivity to anticoagulation with dabigatran, with thera-
peutic doses having minimal effect; these tests are there-
fore not recommended [31]. Thrombin-generation assays
and viscoelastic testing parameters have also been consid-
ered, but thrombin-generation assays are mostly restricted
to research settings and viscoelastic testing has not been
validated for the monitoring of dabigatran in a clinical set-
ting [40]. The aim of testing for dabigatran activity is often
not to provide precise quantification of dabigatran, but
simply to detect the presence or absence of drug in
plasma. This is particularly important in patients with
acute ischaemic stroke, for whom thrombolytic therapy or
procedures requiring high-dose antiplatelet agents are be-
ing considered. Candidate tests are now described in more
detail and are summarised in Table 1.
The aPTT exhibits a non-linear dose response with
increasing concentrations of dabigatran, plateauing at
higher concentrations [31]. In addition, in some patients
taking dabigatran, normal-range aPTT values have been
reported when dabigatran is at trough levels [41]. This
test is therefore not suitable for precise quantification,
particularly at high or low dabigatran concentrations,
but can provide an approximate indication of dabigatran
levels [42]. The aPTT is readily available and therefore is
commonly used to evaluate dabigatran activity or pos-
sible drug ingestion; normal aPTT results reduce the
likelihood of therapeutic anticoagulation.
The thrombin time (TT) exhibits a very steep, linear
dose response with increasing concentrations of dabiga-
tran. This test can be considered excessively sensitive for
the detection of dabigatran activity because samples may
not clot at dabigatran concentrations above 100 ng/ml, a
level within the expected clinical range [41, 43]. There-
fore, the use of this assay for quantifying therapeutic
concentrations of dabigatran is limited. However, the TT
is a very useful assay to determine the presence of low
levels of dabigatran, with TT values within the normal
range suggesting the absence of dabigatran.
The TT and aPTT assays are useful tests in the clinical
setting and can be used in combination, with the TT de-
tecting the presence or absence of drug and the aPTT
providing an approximate indication of the plasma dabi-
gatran concentration. These assays are readily accessible
and can provide information rapidly.
Tests that are used principally for research have also
been considered for assessing dabigatran anticoagula-
tion. For example, dedicated direct thrombin inhibition
assays have a linear relationship over a wide range of
plasma dabigatran concentrations [44]. The dTT is one
type of direct thrombin inhibition assay, in which plasma
is diluted in buffer and then supplemented with normal
human plasma; clotting is then initiated with thrombin.
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This methodology compensates for any coagulation factor
deficiencies and only the effect of the direct thrombin in-
hibition is measured [45]. Ecarin tests, representing an-
other type of direct thrombin inhibition assay, are either
clotting based (ecarin clotting time (ECT)) or chromo-
genic (ecarin chromogenic assay (ECA)) [31, 45]. Ecarin is
snake venom that directly activates prothrombin to initi-
ate clotting, thereby bypassing upstream coagulation and
enabling direct measurement of the influence of the direct
thrombin inhibition. Some ECA tests are supplemented
with prothrombin to allow targeted direct thrombin inhib-
ition quantification independent of any coagulopathies in
the patient sample. In a recent study, the dTT, ECT and
ECA all showed linear correlations with dabigatran con-
centrations over a broad range [41]. Although these tests
are widely available, they are not used in all hospitals [46].
The thrombin-generation parameter ‘lag time’ and, to
some extent, the endogenous thrombin potential (ETP)
have been shown to correlate with plasma dabigatran
concentrations [47]. Recent studies have also shown that
therapeutic dabigatran doses have a significant effect on
the lag time, ETP and peak height, when measured by the
calibrated automated thrombogram (CAT) [48]. However,
thrombin-generation tests are time-consuming and their
availability is generally limited to research laboratories and
centres specialising in haemostasis. Thrombin-generation
parameters therefore cannot be recommended for routine
evaluation of plasma dabigatran concentration.
Viscoelastic tests, including thromboelastometry
(ROTEM®) or thrombelastography (TEG®), can have faster
turnaround times than standard laboratory coagulation
tests because they are whole-blood based and are often
performed in surgical or emergency rooms. This can be
beneficial in emergency situations. The ROTEM® EXTEM
and Rapid TEG (r-TEG) assays measure tissue-factor-
initiated extrinsic coagulation and pre-clinical data have
shown that they are sensitive to dabigatran [49]. There is
anecdotal evidence that dabigatran prolongs the activated
clotting time (ACT) in r-TEG, when all other standard
coagulation tests were within the normal range [50]. How-
ever, neither EXTEM nor r-TEG has been calibrated for
measuring dabigatran levels; in many centres these assays
are not used routinely and there is currently no clinical
evidence supporting the use of these tests for this
purpose.
Prothrombin complex concentrates (activated and
non-activated)
If the patient continues to sustain major blood loss after
initial intervention with haemostatic therapy, or in the set-
ting of intracranial haemorrhage, treatment algorithms
recommend further interventions to counteract the anti-
coagulant effects of dabigatran (Table 2) [28–30, 32].
These interventions include PCCs and aPCCs.
A number of PCCs are commercially available. Detailed
analysis of constituent differences between these products
has been published previously [51]. All PCCs contain the
vitamin K-dependent factors II, IX and X, and are standar-
dised according to their factor IX content. In addition,
they contain differing amounts of factor VII; products
with low or high quantities of factor VII are known as
three-factor or four-factor PCCs, respectively. Some PCCs
also contain anticoagulation proteins such as protein C,
protein S, protein Z, antithrombin and heparin. Further-
more, aPCCs are available which contain non-activated
factors II, IX and X, and activated factor VII.
VKAs (e.g. warfarin) produce their anticoagulant ef-
fects by inhibiting the synthesis of vitamin K-dependent
Table 1 Clinical and research tests available for the assessment of plasma dabigatran concentration
Test Sensitivity to plasma
dabigatran concentration
Availability Clinical recommendation
Thrombin time Linear dose response;
oversensitive
Widely available Recommended for detection of presence or
absence of dabigatran activity
Activated partial thromboplastin time (aPTT) Non-linear dose response Widely available Recommended for semi-quantitative estimation
of dabigatran activity; normal aPTT does not
always exclude presence of dabigatran




Recommended for measurement of plasma
concentration; ECT usually a local assay because
commercial kits not available; not validated
for dabigatran
Diluted thrombin time




Sensitive Limited availability Potential measurement of effectiveness of
treatment for dabigatran-induced anticoagulation;
not validated for dabigatran
Thrombin-generation assays Sensitive (lag time) Limited availability Potential measurement of effectiveness of
treatment for dabigatran-induced
anticoagulation; not validated for dabigatran
Prothrombin time or international
normalised ratio
Low sensitivity Widely available Not recommended in this setting
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coagulation factors II, VII, IX and X. In patients with
life-threatening bleeding, rapid replacement of these co-
agulation factors is required and therefore PCCs are a
reasonable option. Both three-factor and four-factor
PCCs have been investigated for the reversal of VKAs;
four-factor PCCs are more commonly used, because
three-factor PCCs do not provide adequate reductions in
INR owing to the low levels of factor VII [52]. The first
four-factor PCC was approved in the United States in
2013, specifically for this purpose [53]. Nevertheless, in
VKA-associated bleeding, data for PCCs are based prin-
cipally on laboratory rather than clinical endpoints,
meaning that the evidence may be considered not to be
at the highest level.
For the treatment of dabigatran-induced anticoagula-
tion, neither PCCs nor aPCCs act as specific reversal
agents for dabigatran or any other DOAC. Instead, they
raise levels of the vitamin K-dependent coagulation fac-
tors, notably prothrombin, and thrombin generation is
consequently increased. In the case of dabigatran, the
plasma concentration of thrombin is increased to a stoi-
chiometric excess vs the drug, and therefore levels of
free (unbound) dabigatran and the antithrombotic effect
of the drug are minimised. Data from pre-clinical and
clinical studies of PCCs and aPCCs for reversal of dabi-
gatran (see later sections) are consistent with this mech-
anism of action.
Although a number of suitable tests for the monitoring
of plasma dabigatran concentration have been identified,
it does not necessarily follow that these are the most ap-
propriate tests for monitoring the reversal of dabigatran-
induced anticoagulation by PCCs or aPCCs. For example,
the aPTT may be useful in providing an approximate indi-
cation of dabigatran levels, but appears to be insensitive to
the reversal effects of PCCs and aPCCs [49]. There is
some evidence to suggest that the EXTEM assay parame-
ters clotting time (CT) and clot formation time (CFT) are
sensitive to the effects of PCCs and aPCCs on dabigatran
anticoagulation; therefore, these parameters may poten-
tially provide a means of monitoring dabigatran reversal,
although clinical studies are warranted [49].
Efficacy of PCCs and aPCCs for treating
dabigatran-induced anticoagulation
The efficacy of PCCs/aPCCs to treat dabigatran-induced
anticoagulation has been investigated in several pre-clinical
Table 2 Recommendations and algorithms for the management of bleeding patients with dabigatran-induced anticoagulation
Reference Mild bleeding Moderate-to-severe bleeding Life-threatening bleeding or intracranial haemorrhage
Weitz et al., 2012 [32] Discontinue treatment
until bleeding resolves
Sequential treatment: aPCC (50 IU/kg)
(1) PCC (40 IU/kg) If unavailable, give PCC (40 IU/kg) or rFVIIa (90 μg/kg)
(2) aPCC (50 IU/kg)
(3) rFVIIa (90 μg/kg)
(4) Haemodialysis for 6–8 h
or charcoal filtration
Faraoni et al., 2015 [29] No recommendation given No recommendation given (1) Monitor blood loss and perform coagulation assays
(2) Standard resuscitation with fluid therapy, tranexamic
acid (1 g), RBCs and massive transfusion protocola
(3) Four-factor PCC (25–50 IU/kg), aPCC
(FEIBA; 30–50 IU/kg)
EHRA guidelines [30] Maintain diuresis Same recommendation
as for mild bleeding
PCC 50 U/kg (additional 25 U/kg if clinically needed)
aPCC 50 U/kg (maximum 200 U/kg/day)
rFVIIa (90 μg/kg)
Idarucizumab 5 g intravenously
Local haemostatic measures
Fluid replacement
RBC substitution if necessary
Platelet substitution
if necessary
FFP as plasma expander




ESA guidelines [28] No recommendation given No recommendation given PCC, aPCC or rFVIIa may be used as non-specific
antagonists
aTransfusion of FFP/platelets/RBCs
aPCC activated prothrombin complex concentrate, EHRA European Heart Rhythm Association, ESA European Society of Anaesthesiology, FFP fresh frozen plasma,
PCC prothrombin complex concentrate, RBC red blood cell, rFVIIa, recombinant activated factor VII, FEIBA, factor eight inhibitor bypassing activity
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studies, clinical studies and case reports; these are sum-
marised in this section and in Tables 3, 4 and 5.
Pre-clinical animal studies
A mouse model of intracerebral haemorrhage was devel-
oped to test the efficacy of PCC in preventing haema-
toma growth associated with dabigatran treatment [54].
Compared with controls, dabigatran etexilate (9.0 mg/
kg; n = 391) significantly increased the haematoma vol-
ume (17.0 mm3 vs 11.9 mm3; p = < 0.05). The adminis-
tration of 100 U/kg PCC, 30 minutes after the induction
of intracerebral haemorrhage, effectively prevented dabi-
gatran from increasing the haematoma volume (11.7 mm3;
p < 0.05 vs dabigatran alone) and significantly reduced 24-
hour mortality (4 % vs 30 % in mice receiving dabigatran
alone; p < 0.05) [54].
Another study assessed the efficacy of PCC in the treat-
ment of dabigatran-induced anticoagulation in a rabbit
model [55]. Rabbits were given 0.4 mg/kg dabigatran (n =
20) and, 5 minutes later, PCC (20, 35 or 50 IU/kg) or pla-
cebo. After another 5 minutes, a standardised kidney inci-
sion injury was created. Compared with placebo, PCC
produced a dose-dependent reduction in blood loss and
acceleration in haemostasis.
A more recent study in rabbits assessed the efficacy of
PCC for the treatment of dabigatran-induced anticoagula-
tion, using different doses of both drugs [56]. Dabigatran
was administered to anaesthetised rabbits as a 0, 75, 200 or
450 μg/kg bolus dose, followed by continuous infusion to
maintain the post-bolus plasma dabigatran level. After
15 minutes, animals were given PCC doses of 0, 50 or
300 IU/kg and subjected to standardised kidney injury. The
increase in blood loss induced by dabigatran was effectively
attenuated by PCC. In addition, the thromboembolic risk
associated with PCC (measured by histopathological exam-
ination of lung, kidney, heart and brain tissue) was reduced
by the presence of dabigatran [56].
Both PCC and aPCC have been shown to be effective
in treating the anticoagulant effect of dabigatran ex vivo
in a porcine trauma model [49]. Dabigatran etexilate was
given to animals (n = 5) orally for 3 days prior to surgery
and intravenously on day 4 to achieve a supratherapeutic
plasma dabigatran concentration (mean 1423 ng/ml).
Following standardised blunt liver injury, blood samples
were taken and PCC or aPCC (concentrations equivalent
to doses of 30 and 60 U/kg) was added ex vivo. Both
PCC and aPCC diminished the effects of dabigatran and
trauma-induced coagulopathy. No differences were ob-
served between PCC and aPCC [49].
In a similar porcine model of trauma with dabigatran
anticoagulation, some animals received tranexamic acid
(20 mg/kg) and fibrinogen concentrate (80 mg/kg) follow-
ing trauma, before ex-vivo administration of PCC [18].
PCC administration effectively reduced dabigatran-induced
anticoagulation, as shown by significant decreases in PT,
EXTEM CT and EXTEM CFT. PCC also yielded add-
itional coagulation improvements among animals treated
with tranexamic acid and fibrinogen concentrate. The ex-
vivo study design precluded assessment of the effects of
PCC/aPCC on blood loss; consequently, two additional
studies were performed using the same model of injury,
with in-vivo administration of PCC or aPCC.
In the first of these studies, animals receiving dabiga-
tran and polytrauma were randomly assigned to receive
saline control or aPCC (25 or 50 IU/kg) [57]. Blood loss
was not significantly different between animals in the con-
trol and 25 IU/kg aPCC groups (3807 ml and 3690 ml, re-
spectively); however, 50 IU/kg aPCC was associated with
blood loss of 1639 ml, a statistically significant reduction
vs control and 25 IU/kg aPCC (p < 0.0001) [57]. aPCC was
shown to produce improvements in PT, in CT and
CFT in the EXTEM and INTEM assays and in thrombin-
generation peak height and ETP; but not in aPTT or ACT.
Three doses of PCC (25, 50 or 100 IU/kg (PCC25,
PCC50 or PCC100)) were compared with saline control in
the second study [58]. Total blood loss was significantly
lower in animals receiving the higher doses of PCC
(PCC50 and PCC100: 1749 ml and 1692 ml, respectively)
than in the control and PCC25 groups (3855 ml and
3588 ml, respectively). All doses of PCC improved the
coagulation parameters INTEM CT, EXTEM CT and
EXTEM CFT vs controls. In addition, PCC50 and
PCC100 produced sustained increases in ETP [58]. Over-
all, this study showed that PCC25 produced similar out-
comes to control, with only PCC50 and PCC100 reducing
blood loss, but that PCC100 is associated with a pro-
coagulant state. The study also confirmed the low sensitiv-
ity of certain coagulation parameters (e.g. ACT, aPTT,
thrombin-generation lag time) to the effects of PCC on
dabigatran anticoagulation.
In summary, these pre-clinical studies have demonstrated
that sufficient doses of both PCC and aPCC (50 IU/kg)
can successfully reverse the effects of dabigatran-induced
anticoagulation in the pre-clinical setting, as shown by im-
provements in coagulation parameters, blood loss and
mortality. The lack of effectiveness of lower doses may be
explained by insufficient increases in thrombin generation.
These studies do not show any significant differences be-
tween PCC and aPCC in the reduction of bleeding or the
degree of thrombin generation. In addition, the lack of
sensitivity of the aPTT test emphasises the importance of
selecting an appropriate coagulation test for monitoring
dabigatran reversal by PCCs or aPCCs [18, 49]. It is im-
portant to note that in the porcine studies the examined
doses of PCC and aPCC were sufficient to control bleed-
ing under high dabigatran concentrations; lower doses
would almost certainly be adequate with lower, thera-
peutic plasma concentrations of dabigatran.
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Table 3 Pre-clinical studies investigating the use of PCCs and aPCCs to reverse dabigatran-induced anticoagulation
Reference Study design Dose Main results Conclusion
Dabigatran (mg/kg) PCC (IU/kg)
Zhou et al., 2011 [54] Murine intracerebral
haemorrhage model
9.0 100 Haematoma volume: PCC effectively prevented haematoma growth
and significantly reduced 24-h mortality
Post-dabigatran: 17.0 ± 4.1 mm3
Post-PCC: 11.7 ± 3.0 mm3
Mortality:
Control animals: 30 %
PCC-treated mice: 4 %
Pragst et al., 2012 [55] Leporine standardised
kidney injury model
0.4 20, 35 or 50 Blood loss: PCC resulted in a dose-dependent reduction
in blood loss and acceleration in haemostasis.
At the highest dose, blood loss was normalised
in all animals. All doses of PCC successfully
treated dabigatran-induced anticoagulation
at plasma concentrations similar to those seen
in patients receiving dabigatran
Control: 1.0–7.2 ml
Post-dabigatran: mean 29 ml
Post-PCC: decreased by
5.44 ml per 10 IU/kg PCC
No change in aPTT
PT shortened by 0.335 s
per 10 IU/kg PCC
Herzog et al., 2014 [56] Leporine arterial venous
shunt model
0, 0.075, 0.2, 0.45 0, 5 or 300 Bleeding time: Dabigatran-induced bleeding was effectively
reversed by PCC. The thromboembolic risk
associated with PCC administration appeared
to be reduced due to the persistence of
dabigatran in the plasma
Increasing PCC doses shortened
time to haemostasis for rabbits
treated with 0.2 mg/kg dabigatran
No dose of PCC could reverse
the effects of 0.45 mg/kg
dabigatran on time to haemostasis
Thrombosis:








PCC: PCC: Both PCC and aPCC diminished the effects
of dabigatran, restoring ROTEM® parameters
and PT to 80–90 % of baseline30 or 60 No effect on aPTT
aPCC: aPCC:










Table 3 Pre-clinical studies investigating the use of PCCs and aPCCs to reverse dabigatran-induced anticoagulation (Continued)




aPCC: 50 IU/kg aPCC associated with
significant reduction in blood
loss vs placebo group and
those treated with 25 IU/kg
aPCC (50 IU/kg) is effective in reducing
blood loss in anticoagulated pigs
25 or 50
Lower-dose aPCC (25 IU/kg) had an initial
effect that was not sustained, suggesting
stoichiometric excess of prothrombin vs
dabigatran may be required




30 or 60 Significant decreases in PT, CT and CFT Three-factor and four-factor PCCs are
similarly effective for dabigatran reversal




25, 50 or 100 50 and 100 IU/kg PCC associated with
significant reductions in blood loss vs
placebo group and those treated
with 25 IU/kg
PCC can be effective in reducing blood
loss in anticoagulated pigs
High doses may induce a procoagulant state
Low doses may be ineffectiveHigh-dose PCC (100 IU/kg) led to
overcorrection of thrombin generation










Table 4 Clinical studies investigating the use of PCCs and aPCCs to reverse dabigatran-induced anticoagulation
Reference Study design Dose Main results Conclusion
Dabigatran (mg) PCC (IU/kg)
Eerenberg et al., 2011 [59] Randomised, placebo-controlled crossover
(study included rivaroxaban and dabigatran)
150 50 (administered to
healthy volunteers)
50 IU/kg PCC did not correct aPTT,
thrombin-generation lag time, TT or ECT
PCC did not neutralise the anticoagulant
effect of dabigatran
Marlu et al., 2012 [60] Ex vivo, randomised crossover (study
included rivaroxaban and dabigatran)
150 PCC (in vitro):
12.5, 25 or 50
aPCC (in vitro):
20, 40 or 80
PCC restored changes in ETP at all
three doses
Some non-specific reversal agents appear
able to reverse the anticoagulant activity
of dabigatran
aPCC corrected both ETP and lag time at
doses of 40 and 80 U/kg but not 20 U/kg
Herrmann et al., 2014 [48] Ex vivo, cohort study of patients receiving
dabigatran for non-valvular atrial fibrillation




Dabigatran prolonged aPTT, PT, TT,
dynamic parameters of TEG® and ROTEM®
and thrombin-generation lag time; it also
reduced ETP and thrombin-generation
peak height
Some non-specific reversal agents appear
able to reverse the anticoagulant activity
of dabigatran
All parameters ameliorated by aPCC
All parameters except PT ameliorated
by PCC











Table 5 Case studies investigating the use of PCCs and aPCCs to reverse dabigatran-induced anticoagulation





150 mg twice daily Acute liver failure, acute kidney injury and
anaemia, with upper GI bleeding from an ulcer




78-year-old male with AF,
hypertension and a history
of ischaemic stroke
150 mg twice daily Haematemesis and melena 8 U RBCs Blood loss was promptly reduced and the patient was stabilised
Hb 5.9 g/dl 12 U platelets
Creatinine clearance 26 ml/min 8 U cryoprecipitate
Patient discharged on reduced dabigatran dose
(75 mg twice daily)
aPTT 83 s 40 U/kg PCC
TT > 150 s
Javedani et al.,
2013 [46]
54-year-old male with AF
and hypertension
150 mg twice daily Acute ischaemic stroke 4520 mg PCC Coagulation parameters measured post PCC administration:





Patient was discharged after 7 days on aspirin and warfarin
Schulman et al.,
2014 [61]
84-year-old male with AF 110 mg (unknown
frequency)
Subdural haematoma following a fall 50 U/kg aPCC No immediate change in coagulation profile
TT 127 s Thrombin time normalised after 3 days
aPTT 46 s Bleeding resolved
INR 1.2 Patient discharged on day 4 with complete resolution
of weakness




CT scan identified haemorrhage in left basal ganglia 42 U/kg aPCC Repeat imaging after 3 days showed slight increase in
haematoma sizeaPTT 48 s
Speech normalised on day of admission
TT > 150 s
Motor function required 2 months rehabilitation
Normal mobility and strength but slight right-sided
numbness after 13 weeks
85-year-old female with AF,
hypertension, dyslipidaemia,
chronic kidney disease and
previous myocardial infarction
75 mg twice daily Undergoing insertion of dual-chamber pacemaker 100 U/kg aPCC Bleeding ceased but thrombin time remained
immeasurable for 3 days
aPTT 65 s
Creatinine clearance 27 ml/min
83-year-old female with AF 110 mg twice daily Admitted to hospital with upper GI bleeding 50 U/kg aPCC Clinical condition stabilised following administration of PCC
3 U RBCsHb 99 g/l
Creatinine clearance 24 ml/min
Masotti et al.,
2015 [62]
93-year-old female with AF 110 mg twice daily Major bleeding from GI tract 25 U/kg PCC
at 0 and 6 h
Bleeding ceased, but no improvement in coagulation
parameters was observed after either PCC dose
aPTT 89 s
PT 21 % Tranexamic acid No more re-bleeding occurred
Coagulation parameters normalised after 6 days
(aPTT 28 s, PT 90 %) and patient was discharged
AF atrial fibrillation, aPCC activated prothrombin complex concentrate, aPTT activated partial prothrombin time, FFP fresh frozen plasma, GI gastrointestinal, Hb haemoglobin, INR international normalised ratio, PCC










Clinical studies: healthy volunteers
The first study to assess PCCs for the treatment of
dabigatran-induced anticoagulation in humans was a ran-
domised, placebo-controlled crossover study [59]. Healthy
male volunteers (n = 12) were given either 20 mg rivaroxa-
ban or 150 mg dabigatran twice daily, followed by 50 IU/
kg PCC or saline. Following a suitable washout period,
study participants were switched to the other anticoagu-
lant. The coagulation tests aPTT, ETP, lag time, TT and
ECT were performed to measure the effects of PCC on
the anticoagulation induced by dabigatran. Dabigatran
prolonged the aPTT (p < 0.001), thrombin-generation lag
time (p < 0.001), TT and ECT (p = 0.002) in all subjects.
The 50 IU/kg dose of PCC was not sufficient to normalise
any of these parameters in healthy volunteers [59]. This
result is attributable to the use of endpoints that are not
sensitive to PCC reversal of dabigatran [49]; also, there
may be differences between healthy volunteers without
coagulopathy and clinical patients in whom emergency
dabigatran reversal is needed.
In a randomised, crossover, ex-vivo study, 10 healthy
male subjects were randomised to receive one oral dose
of either dabigatran (150 mg twice daily) or rivaroxaban
(20 mg daily) [60]. After a 2-week washout period, each
patient received the other anticoagulant. In dabigatran-
treated patients, PCC added to blood samples in vitro ef-
fectively reversed dabigatran-induced changes in the ETP
at all three doses (12.5, 25 and 50 IU/kg); aPCC was able
to correct both the ETP and thrombin-generation lag time
at doses of 40–80 U/kg [60].
Clinical studies: patients
In 17 patients receiving 150 mg dabigatran twice daily
for AF following hip or knee arthroplasty, plasma sam-
ples were taken to characterise the anticoagulant effect
[48]. In addition, the effects of ex-vivo addition of PCCs
and aPCCs were investigated using blood samples. Dabi-
gatran administration significantly prolonged a number
of laboratory parameters, including the PT, aPTT and
TT. In addition, the TEG® parameters of reaction time
and alpha angle and the ROTEM® parameters INTEM
CFT and EXTEM CFT were all significantly increased. As-
sessment of thrombin generation using a CAT (Thrombi-
noscope BV, Maastricht, the Netherlands) showed that the
lag time was increased and ETP was decreased. Ex-vivo
addition of 500 mU/ml PCC significantly ameliorated all
parameters with the exception of the PT, and addition of
500 mU/ml aPCC (FEIBA) ameliorated all parameters [48].
Case reports
Several case reports assessing the efficacy of PCCs
and aPCCs for treatment of bleeding associated with
dabigatran-induced anticoagulation have been published.
Case-report outcomes constitute low-quality data and
cannot be considered conclusive because of the small
numbers of patients and variations in aspects such as type
of bleeding, doses of PCC/aPCC and co-morbidities of the
patients. In addition, individual patients are not usually
treated with PCC or aPCC alone, so clinical outcomes are
not necessarily determined specifically by these agents.
Despite these limitations, we consider the published case
reports to be worthy of consideration.
In a case series of four patients with life-threatening
dabigatran-related bleeding (subdural haematoma, intra-
cerebral haemorrhage, surgery for insertion of a pace-
maker and gastrointestinal bleeding), the administration
of aPCC (dose range 42–100 U/kg) was associated with
bleeding being brought under control [61]. A number of
other case reports have also reported successful out-
comes following treatment with PCC or aPCC as a re-
sponse to ischaemic stroke (embolic thrombus of the left
middle cerebral artery) [46] or gastrointestinal bleeding
[23, 32, 62] occurring in patients under dabigatran treat-
ment. However, in some of these cases rFVIIa was ad-
ministered as concomitant therapy, making the specific
impact of PCC/aPCC on dabigatran anticoagulation dif-
ficult to estimate. In contrast, there have also been cases
where the use of PCC alongside rFVIIa has appeared in-
effective, with no improvement of coagulation parame-
ters or reduction of bleeding [63].
Safety of PCCs and aPCCs
The procoagulant/prothrombotic risks of treatment with
PCCs and aPCCs must be weighed against the benefits.
It should be noted that neither PCCs nor aPCCs are
currently licensed for the treatment of DOAC-induced
anticoagulation; therefore, any such use is off-label. The
majority of evidence relating to the safety of PCCs has
been obtained from VKA reversal or non-anticoagulated
patients with perioperative bleeding. These are very
different situations from the emergency treatment of
DOAC-induced anticoagulation, and more evidence is
needed regarding the safety of PCCs in this setting.
Historically, PCCs/aPCCs have been associated with a
risk of thrombotic complications when used for the treat-
ment of haemophilia or VKA reversal [64]. Composition
adjustments, such as the inclusion of coagulation inhibi-
tors, reduced use of activated factors and improved
balance of coagulation factor content, have been imple-
mented with the aim of improving the safety of PCCs [65].
Relative levels of factor II (prothrombin) and the key in-
hibitor antithrombin have been identified as the major
cause of thrombogenicity [66]. In an observational study
in trauma patients, PCC was shown to increase the ETP
for 3–4 days following treatment (i.e. approximately the
half-life of prothrombin) [67]. In addition, patients receiv-
ing PCC had low levels of antithrombin. It has been
suggested that PCCs should be labelled according to
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prothrombin content, rather than factor IX content [66].
Overall, the available safety data indicate that there are
possible risks when using PCCs.
An in-vivo animal study assessed the safety of PCC for
the treatment of dabigatran-induced anticoagulation [56].
In the absence of dabigatran, high-dose PCC (300 IU/kg)
produced low-grade pulmonary emboli in 5/5 (100 %) of
animals. However, when the same dose of PCC was ad-
ministered to animals previously treated with dabigatran,
the frequency of pulmonary emboli was decreased in the
presence of dabigatran in a dose-dependent manner (2/5
(40 %) at a dabigatran dose of 75 μg/kg, 1/5 (20 %) at
200 μg/kg and 0/5 (0 %) at 450 μg/kg) [56].
In a porcine model of coagulopathy with blunt liver in-
jury and no anticoagulation, administration of a four-factor
PCC (50 IU/kg) resulted in protracted elevation of throm-
bin–antithrombin complexes and D-dimers, and formation
of thromboemboli and pulmonary fibrinogen deposits in
some animals [68]. Signs of disseminated intravascular co-
agulation were also shown in 44 % of animals. In contrast,
a PCC dose of 35 IU/kg safely improved coagulation pa-
rameters and halted blood loss. Furthermore, survival and
total blood loss were significantly improved in both PCC
groups when compared with control animals [68].
In contrast to the previous study, the administration of
PCCs or aPCCs to pigs after blunt liver injury under
high-dose dabigatran appears not to be associated with
thromboembolic events. Histopathological assessments
showed that there was no thrombus formation in the
heart, lungs, liver and kidneys after administration of PCC
(25, 50 or 100 IU/kg) [58] or aPCC (25 or 50 IU/kg) [57].
Clinical perspective and conclusion
DOACs such as dabigatran have proven effective in de-
creasing the risk of ischaemic stroke in patients with AF,
and in the prevention and long-term treatment of VTE.
Although the bleeding risk associated with dabigatran is
low, any anticoagulant can cause bleeding. With life-
threatening bleeding in dabigatran-treated patients, urgent
reversal of the thrombin inhibitory effects of dabigatran
should be considered. The available data indicate that
PCCs and aPCCs may be able to reverse dabigatran-
induced anticoagulation in a dose-dependent manner.
However, we do not have high-level evidence to support
the use of PCCs/aPCCs in this setting, so the recommenda-
tion to use them is based on haematological principles, ani-
mal studies, healthy volunteer studies, an ex-vivo study of
‘real-world’ patients, and outcomes in a few case reports.
Treatment with PCCs or aPCCs increases the concen-
trations of several coagulation factors, including pro-
thrombin which has a half-life of 60–72 hours [51].
Thrombin generation may therefore be enhanced for sev-
eral days after the use of PCCs to treat major bleeding
[67]. This may be associated with an increased risk of
thromboembolic events. The lack of high-level evidence
with PCCs and aPCCs for dabigatran reversal makes it dif-
ficult to make dose recommendations, but it appears ne-
cessary to use the minimum effective dose. On the other
hand, there is evidence that low doses may not be effective
in reversing the anticoagulant effects of dabigatran, prob-
ably because of the need to increase the plasma concen-
tration of thrombin to that of dabigatran [58]. This
scenario is complicated by the lack of specific coagulation
tests that are routinely available and rapid to perform,
with established sensitivity and specificity for guiding the
required dose of PCC or aPCC and then monitoring the
effects of treatment. There is a clear need for a test that
fulfils these criteria. Against this background, it is unsur-
prising that there are variations between guidelines for the
use of PCCs/aPCCs in the management of bleeding
among dabigatran-treated patients. Treatment decisions
will be made on a case-by-case basis according to clinical
judgement, local hospital protocols and product availabil-
ity. Because of the theoretical thromboembolic risk, it is
reasonable to titrate PCCs/aPCCs according to the clinical
condition of the patient, starting with an initial dose of
25 IU/kg. However, clinical data are needed to establish
the optimum dosing strategy. Because the mechanisms of
action of PCCs and aPCCs are similar (both act by in-
creasing thrombin generation), there is no need to use
first one and then the other in a step-wise approach to
bleeding management. It is essential to remember that the
anticoagulant effect of dabigatran may be only one aspect
contributing to coagulopathy; the likelihood of coexistent
hyperfibrinolysis, dilutional coagulopathy and loss of co-
agulation factors, etc. [69] require a multi-therapeutic ap-
proach. In the future, once the specific reversal agent
idarucizumab becomes widely available, this treatment will
be considered preferable to PCCs and aPCCs for dabiga-
tran reversal because it has not been associated with a risk
of thromboembolic events and has shown no procoagu-
lant effect in various laboratory analyses. The phase III
RE-VERSE AD study of idarucizumab showed complete
reversal of the anticoagulant effect of dabigatran within
minutes, in patients with serious bleeding or who required
an urgent procedure [19]. However, idarucizumab may
not be available at every hospital for quite some time.
Also, there could conceivably be clinical circumstances
under which PCCs or aPCCs might be valuable as part of
multimodal therapy, such as when thrombin generation is
impaired as a result of trauma-induced coagulopathy [70],
although this needs to be evaluated in clinical studies.
Conclusions
Certainly at present, PCCs and aPCCs are far more
widely available than idarucizumab, meaning that their
use for emergency reversal of dabigatran among bleeding
patients may be warranted. The available data do not
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provide evidence that either PCCs or aPCCs should be
considered preferable to the other. RCTs are required to
provide a robust evidence base, to ascertain the optimum
dosing strategy and to determine the relative effectiveness
of PCCs and aPCCs in this setting.
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